168 related articles for article (PubMed ID: 19355963)
21. [Usage of interferon inducers during viral infections].
Ershov FI; Narovlyansky AN
Vopr Virusol; 2015; 60(2):5-10. PubMed ID: 26182650
[TBL] [Abstract][Full Text] [Related]
22. [Effect of low-molecular interferon inducers in experimental hepatitis in mice].
Tazulakhova EB; Saĭitkulov AM; Barinskiĭ IF; Ershov FI
Vopr Virusol; 1988; 33(2):179-81. PubMed ID: 2457987
[TBL] [Abstract][Full Text] [Related]
23. [Role of cycloferon and interferon-alphain apoptosis regulation in neuroendocrinal system on aging].
Bazhanova ED
Eksp Klin Farmakol; 2012; 75(10):42-6. PubMed ID: 23240158
[TBL] [Abstract][Full Text] [Related]
24. [The antibacterial efficacy of preparations of interferon and its inducers].
Spivak NIa; Grabchenko NI; Lazarenko LN; Tovt-Korshinskaia MI; Ganova LA; Timoshok NA; Krivokhatskaia LD; Mikhaĭlenko ON; Karpov AV; Mikhaĭlenko TI; Zotsenko VN
Mikrobiol Z; 1999; 61(1):32-45. PubMed ID: 10330873
[TBL] [Abstract][Full Text] [Related]
25. [Rational pharmacotherapy and correction of immunity disorders in children with chronic hepatitis (clinical review)].
Goriacheva LG; Romantsov MG; Agaeva SG; Lin'kov IuN; Kovalenko AL
Antibiot Khimioter; 2010; 55(5-6):50-7. PubMed ID: 21033475
[TBL] [Abstract][Full Text] [Related]
26. [Interrelationship between the chain length of poly-L-lysine and the degree of protection of polyribonucleotide interferon inducers from human blood nucleases].
Surzhik MA; Duks AE; Diatlova NG; Glazunov EA; Feldmane GIa; Timkovskiĭ AL
Antibiot Khimioter; 1993 Jul; 38(7):21-5. PubMed ID: 8161271
[TBL] [Abstract][Full Text] [Related]
27. [Dynamics of interferon induction in albino mice by interferon inducer ridostin administered by various routes].
Bulychev LE; Goncharova EP; Ryzhikov AB; Masycheva VI; P'iankova OG; Pliasunov IV; Poryvaev VD; Kotliarov LA; Kolesnikova NG
Antibiot Khimioter; 1998; 43(4):20-3. PubMed ID: 9606500
[TBL] [Abstract][Full Text] [Related]
28. [Resistance of natural and synthetic polyribonucleotide inducers of interferon to human blood ribonucleases].
Surzhik MA; Diatlova NG; Glazunov EA; Timkovskiĭ AL; Vlasov GP; Kozhevnikova NIu
Antibiot Khimioter; 1992 Jan; 37(1):21-3. PubMed ID: 1530353
[TBL] [Abstract][Full Text] [Related]
29. [Effect of amyxin--a domestic analog of tilorone--on characteristics of interferon and immune status of man].
Sel'kova EP; Semenenko TA; Nosik NN; Iudina TI; Amarian MP; Lavrukhina LA; Pantiukhova TN; Tarasova GIu
Zh Mikrobiol Epidemiol Immunobiol; 2001; (4):31-5. PubMed ID: 11569258
[TBL] [Abstract][Full Text] [Related]
30. [Perspectives on interferon research and on its therapeutic use].
Montagnier L
Arch Inst Pasteur Tunis; 1981; 58(3):297-312. PubMed ID: 6172080
[TBL] [Abstract][Full Text] [Related]
31. [Combined experimental use of vaccine against acute human encephalomyelitis and immunomodulators].
Ignat'ev GM; Tazulakhova EB; Borsuk EA; Morozov NS; Razvorotnev VA; Vorob'eva MS
Antibiot Khimioter; 1992 Jul; 37(7):28-31. PubMed ID: 1280938
[TBL] [Abstract][Full Text] [Related]
32. [Effect of interferon inductors on infection induced by hepatitis C virus and activity of mRNA cytokines in cell cultures SW-13 and MT-4].
Narovlianskiĭ AN; Deriabin PG; Vershinina MIu; Mezentseva MV; Ershov FI
Vopr Virusol; 2002; 47(6):17-21. PubMed ID: 12508677
[TBL] [Abstract][Full Text] [Related]
33. [Medical and commercial aspects of human interferon].
von Eichborn JF
Arzneimittelforschung; 1986 Feb; 36(2):279-82. PubMed ID: 2421742
[TBL] [Abstract][Full Text] [Related]
34. Antiviral activity of a synthetic double-stranded polyribonucleotide interferon inducer in a murine AIDS retrovirus model. Role of augmentation of natural killer cell activity and synergy with oral AZT.
Black PL; McKinnon KM; Wooden SL; Ussery MA
Ann N Y Acad Sci; 1993 Jun; 685():467-70. PubMed ID: 8363255
[No Abstract] [Full Text] [Related]
35. [The use of the ultrasonic spraying of interferon and larifan solutions for treating acute herpetic stomatitis in children].
Mamedova SA; Gashimov RG; Bikbulatov RM
Stomatologiia (Mosk); 1991; (5):68-70. PubMed ID: 1724712
[TBL] [Abstract][Full Text] [Related]
36. [The use of cycloferon in the therapy of experimental herpetic keratitis].
Sukhinin VP; Pleskov VM; Zarubaev VV; Slita AV; Pestrinskaia EA; Brzheskiĭ VV; Kovalenko AL; Ershov FI
Antibiot Khimioter; 2000; 45(6):13-6. PubMed ID: 10904803
[TBL] [Abstract][Full Text] [Related]
37. [Peculiarities of immunomodulating therapy in an immunocompromised patient with allergies].
Klin Med (Mosk); 2011; 89(5):60-4. PubMed ID: 22242271
[TBL] [Abstract][Full Text] [Related]
38. [Detection of the interferon deficiency in inflammatory gynecological diseases and its correction with interferon inducers].
Ospel'nikova TP
Georgian Med News; 2012 Nov; (212):24-32. PubMed ID: 23221135
[TBL] [Abstract][Full Text] [Related]
39. [The experimental and clinical antitumor action of the interferon inducer larifan].
Gasparian MG; Dzhagatspanian NG; Gevorkian RA; Kamalian LA
Vopr Virusol; 1991; 36(2):127-30. PubMed ID: 1909072
[TBL] [Abstract][Full Text] [Related]
40. Human interferon and its inducers: clinical program overview at Roswell Park Memorial Institute.
Carter WA; Horoszewicz JS
Cancer Treat Rep; 1978 Nov; 62(11):1897-8. PubMed ID: 728908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
